Inmaculada Hernandez, PharmD, PhD

Inmaculada (Inma) Hernandez, PharmD, PhD, is an assistant professor at the University of Pittsburgh School of Pharmacy. Her research program is built at the intersection of pharmaceutical health services and outcomes research, pharmacoepidemiology, pharmacoeconomics, and pharmaceutical policy. Specifically, she is interested in the real-world use and outcomes of oral anticoagulation therapy in stroke prevention in atrial fibrillation, on the use of large data sets, advanced data mining techniques, and comparative effectiveness research to predict and compare outcomes of medications, and on value-based health insurance and health services delivery.
September 24, 2017
Outcomes-based pricing arrangements for pharmaceuticals are increasingly popular. In this piece, we discuss the impact of the outcomes-based pricing arrangements proposed by Amgen on the pricing of PCSK9 inhibitor therapy, and we provide recommendations for payers on the design of outcomes-based contracts.
January 04, 2016
Using the case of oral contraceptives as an example, I explain the differences between off-label and off-guideline prescription, and explain how the inappropriate use of oral contraceptives could be reduced by the regulation of off-guideline prescription.
November 10, 2015
Oral contraception, the most widely used contraceptive method in the US, is associated with an increased risk of cardiovascular side effects. Despite increased awareness of this risk over the years, the use of oral contraceptives among women with conditions that place them at high risk for cardiovascular effects is still common.
August 10, 2015
Despite harsh measures imposed by the Eurogroup, a third bailout is arguably a better scenario from the perspective of access to healthcare in Greece than a potential exit from the Eurozone.
July 01, 2015
The health coverage of millions of Americans in 34 states was pending upon the Supreme Court decision on the King v Burwell case. Luckily, common sense prevailed and the Supreme Court based its ruling on the original motivation behind the creation of the exchanges rather than on the plain language used in the provision.
June 15, 2015
The availability of dabigatran 110 mg in the US may be a favorable therapeutic option for patients at high risk of bleeding, who may be willing to accept a higher probability of stroke for a reduced risk of hemorrhage
April 20, 2015
What can the US learn from the UK National Health System? Probably not acute care management, but definitely, primary care and preventive interventions.
April 01, 2015
Aggressive policies that target the use and promotion of off-label use are needed to prevent the use of drugs for non-approved indications with little benefit or with harmful outcomes.
Copyright AJMC 2006-2018 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
×

Sign In

Not a member? Sign up now!